| Typicality: | 0.491 |
| Saliency: | 0.413 |
| for the treatment of advanced rcc | 12 | purpose |
| in 1993 | 4 | temporal |
| in the dpp-4 enzyme | 3 | other |
| agent → be approved by → the fda | 22 |
| agent → be approved by → the food and drug administration | 9 |
| agent → be → fda-approved | 6 |
| negative | neutral | positive |
| 0.059 | 0.645 | 0.296 |
| Raw frequency | 37 |
| Normalized frequency | 0.413 |
| Modifier score | 0.700 |
| Perplexity | 40.322 |